In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their ...

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).

and diabetic macular oedema (DMO - and will be sold in the EU by Biogen. Like Lucentis, the biosimilar can also be used to treat proliferative diabetic retinopathy (PDR), macular oedema caused by ...

This swelling can lead to serious vision problems ... following its 2021 approval for wet (neovascular) age-related macular degeneration. The ranibizumab injection (Lucentis) was first approved ...

Diabetic macular edema occurs when fluid leaks from blood vessels in the retina, causing swelling in the macula that can lead to vision loss in people with diabetes. Let's explore the latest ...

TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® ...